Medical devices, healthcare technology and the business of care
PMA approval · P160042

REVANESSE ULTRA

Prollenium Medical Technologies, Inc. · Decision date Aug 4, 2017

MEDTECHLEDGER EXPLANATIONP160042

What did the FDA approve?

FDA approved PMA P160042 for Revanesse Ultra on August 4, 2017. The approval statement describes the device as an implant for aesthetic use, indicated for injection into the mid to deep dermis to correct moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more. The applicant is Prollenium Medical Technologies, Inc., and the product code is LMH.

The record identifies this as an original PMA approval, not a supplement or manufacturing notice. The statement reports the intended use as stated by the applicant; it does not independently establish safety or clinical effectiveness. No supplement type or supplement reason is listed, and the source does not include clinical data, trial information, or comparative performance details.

FDA approval order statement

Approval for the Revanesse Ultra. The device is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults 22 years of age or more.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Aug 4, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P160042
Regulatory pathway
Premarket approval application
Product code
LMH
Decision code
APPR
Decision date
Aug 4, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P160042 received

    Application receipt date recorded by FDA.

  2. P160042 · FDA decision

    APPR

  3. P160042/S032 · Related supplement

    Revanesse Versa, Revanesse Versa+ (with lidocaine) and Revanesse Lips+ (with lidocaine)

Timeline entries are records held by MedtechLedger for P160042. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160042

Product / regulatory recordCompanyPathwayDecision dateSource
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Prollenium Medical Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
138 Industrial Pkwy. N., Aurora, L4G 4C3

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records